Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Janssen-Cilag International NV
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03852160CT.gov A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression | — | Withdrawn | — | — | — |
NCT05531591CT.gov RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT) | — | Completed | — | — | — |
NCT03993457CT.gov Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression | — | Terminated | — | — | — |
NCT04039022CT.gov Open-Label Safety Study of AXS-05 in Subjects With Depression | — | Completed | — | — | — |
NCT03219008CT.gov Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics | — | Unknown | — | — | — |
NCT02960763CT.gov Optimizing Outcomes of Treatment-Resistant Depression in Older Adults | — | Completed | — | — | — |
NCT02374567CT.gov Pharmacovigilance in Gerontopsychiatric Patients | — | Terminated | — | — | — |
NCT01942187CT.gov A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults | — | Withdrawn | — | — | — |
NCT01407094CT.gov Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression | — | Completed | — | — | — |
NCT01748955CT.gov Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study | — | Completed | — | — | — |
Show 7 more trialsShow fewer
NCT01305707CT.gov Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression | — | Terminated | — | — | — |
NCT00917059CT.gov Personalized Indicators for Predicting Response to SSRI Treatment in Major Depression (The PRISE-MD Study) | — | Completed | — | — | — |
NCT00624858CT.gov A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression | — | Completed | — | — | — |
NCT00531518CT.gov Early Detection and Intervention for the Prevention of Psychosis | — | Completed | — | — | — |
NCT00296933CT.gov Memory Functioning and Antidepressant Treatment | — | Completed | — | — | — |
NCT00125957CT.gov The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression | — | Completed | — | — | — |
NCT00181896CT.gov Bupropion SR for Major Depression and Depression NOS in Children and Adolescents With Bipolar Disorder | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bupropion (this asset) | Janssen-Cilag International NV | Approved | BB · 71 |
| Brexpiprazole | Dr. Albert Kar-Kin Chung | P4 | A |
| Saredutant | Sanofi | P3 | BBB |
| Jnj-54135419 | Chinese PLA General Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | VA Office of Research and Development | P4 | BBB |
| Citalopram | Western University, Canada | P4 | BBB |
| Fluoxetine | University of Oxford | P4 | BBB |
| Escitalopram | Poznan University of Medical Sciences | P4 | BBB |
| Lithium, Elemental | Rakitzi, Stavroula | P4 | BBB |
+42 more in the Depressive Disorder cohort
Other indications for Bupropion
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bupropion in Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bupropion-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →